Allo-hMSCs + Placebo

Phase 1Terminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypoplastic Left Heart Syndrome

Conditions

Hypoplastic Left Heart Syndrome

Trial Timeline

Apr 1, 2015 → Mar 1, 2019

NCT ID

NCT02398604

About Allo-hMSCs + Placebo

Allo-hMSCs + Placebo is a phase 1 stage product being developed by Longeveron for Hypoplastic Left Heart Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02398604. Target conditions include Hypoplastic Left Heart Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02398604	Phase 1	Terminated	Apr 1, 2015	Mar 1, 2019	Hypoplastic Left Heart Syndrome

Competing Products

1 competing product in Hypoplastic Left Heart Syndrome

See all competitors

Product	Company	Stage	Hype Score
Lomecel-B medicinal signaling cells	Longeveron	Phase 2	44

Other Products from Longeveron

Allogeneic MSCPhase 2

Longeveron Mesenchymal Stem Cells (LMSCs)Phase 2

Lomecel-B medicinal signaling cellsPhase 2

Peripheral Intravenous (IV) infusion of LMSCsPhase 2

Longeveron Mesenchymal Stem CellsPhase 1/2